At least one adverse event in 15.0% of the patients treated with MMX mesalazine and in 28.0% of those treated with enemas were recorded.
Se registró al menos un acontecimiento adverso en el 15,0% de los pacientes tratados con mesalazina-MMX y en el 28,0% de los tratados con enemas.